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Objectives. The purpose of this study was to evaloale the effrets 
of vawdilator combinalioo therapy in patienb with primary 
pohnonary hypertension. 
Background. Calcium channel blockers and adenosine have 
each been shown to be &e&e in reducing pulmonary artery 
pressure and pubnonary vascular resistance in patienls with 
primary pulmonary hypertension. However, the e@xl~ of com- 
biiiog these wodilators have nd been studied. 
Melkods. To tesl the mmbination, 12 p&eats WP~P placed oa 
oral nifodipine and 3 oo dilliwm therapy, usiog a doso titrated lo 
maximal effect (mean nifedipine dose 103 f 24 mg, mean tilt- 
laxem dose 300 * 49 mg). Patients were then @en maintenance 
dosn of ihe calcium channel blocker at half the cumul&e 
loading dose at 6-h intervals. One hour after the maintenance dose 
of ealeium blocker, all patienu wived an infusion oi adenmine, 
starting with 50 &kg per min and bxreasing by 50 mg per 
min at tlain intervals to a maximally tolcraled dose (180 I 
63 &kg per InhI). 
Results. Tea patients responded lo calcium channel blockers 
When titrated to maximal physiologic electiveness, catcium 
chanwl blockers have been shown 10 lower pulmonary 
vascular resistance in up to 72% of patients whh primwy 
pulmonary hypertension. These agents have also been 
shown to decrease pulmonary artery pressure substantially 
in as many as 30% of such patients (I-3). 
Adenosine, an intermediate product in the metabolism of 
adenosine triphosphate. has beeu shown to be a potent 
vasodilator through actions on specific vascular receptors 
(4). It produces coronary vasodilation (51, decreases sys- 
temic vascular resistawe (61 and causes relaxmion of human 
pulmonary arteries in viva (7). In a previous study (8). 
adenosine decreased pulmonary vascular renisrance by 
. m: Sluan Rich, MD. University 01 Illinois at 
Chicago. Se&n 9 CwJiology. (M/C 7871. Roam 929. 840 Swth Wood 
Sweet. CXcago. lllinolr 60512. 
(defined as a 220% decrease in pulmowy VW&~ re&awe), 
6th B 16% decrew in mean pulmenq artery presswe (p = 
0.0571, a 39% decrease in puhooaaq vase&r wsisiwx (p = 
0.002) and a 24% iocrease in stroke vcduroe (p = 0.007). Fipe 
patients were noarqmndws, wilh no 
>?O% in 80% of patienls with pulmonary hypertension, an 
effect that was similar lo the response to nifedipine. 
The therapeutic elfects of combining more than one 
vasodilator have not been well studied in pulmonary hyper- 
tension. Combination therapy may be appealing because 
vasodilators may have additive hemodynamic effects 
through diffe,cnt mechanisms of action or. alternatively. a 
common mechanism that may not be saturated by one drug 
before side effects develop and limit the dosing. 
This study was designed to assess the acule hemody- 
namic eiieecrs of maximally tolerated doses of adenosine on 
the pulmonary circulation in patients with primary pulmo- 
nary hypericnsion who had been treated acutely with cal- 
cium channel blockers Waled lo maximal effecrivefless. 
Fifteen consecutive patients referred lo the University of 
Illinois Hospital for evaluation of primary pulmonary hyper- 
tension between luly 1990 and Sepicmber 1991 were en- 
rolled in the study. The study protocol was reviewed and 
approved by the University of Illinois Institutional Review 
Board There were II women and 4 men (mean age 43 * 
8.8 years). AU patients had a thorough evaluation to identify 
the cause of their pulmonary hypertension, including a chest 
radioaraoh. lune scan. aulmonaw function testina, echocar- 
dioa&hv and ~thetehxation. accordine to the &co1 of 
the&i&al Institutes of H&h Prima&Puln&uy Hyper- 
tension Registry (9). After an overnight fast, all patients 
underwent diagnostic right heart catheterization to assess 
hemodynamic variables. AU medications except digoxin and 
diuretic drues were discontinued rZ weeksbefore the studv. 
A 7F Swani3anz catheter was placed into the pulmonary 
artery and a small Telon eatheter was placed in the femoral 
artery to monitor systemic pressures. Cardiac output was 
determined by the thermodilution technique. Systemic and 
pulmonary artery pressures were measured, with values for 
pulmonary vascular resistance 2nd systemic vascular resis- 
tance calculated by standard formulas. 
Caicium channel blocker MmhWWn. After ighI heart 
catheterization, patients were transferred to the coronary 
care unit, where periodic measurements of ystemic and 
pulmonary pressures and cardiac output were taken until 
stable values were obtained, and then hourly thereafter. The 
protocol for calcium channel blocker administration has 
been described in detail (3). Briefly, patients received an 
hourly dose of either 20 mg of nifedipine or, if they had 
tachycardia at rest (heart rate ~100 beatslmin), 60 mg of 
diltiazem. The &active doss of each agent was established 
by hourly administration of the drug until the greatest 
reduction in pulmonary vascular resistance tolerated by the 
patient was achieved. Patients were then given maintenance 
doses of the calcium channel blocker at a dose that was half 
the cumulative loading dose at 6-h intervals. 
Adenasine admhdstration. One hour after the last calcium 
channel blocker dose, patients were given adenosine into an 
antecubital vein as a continuous infusion. The infusion began 
at 50 &kg Per min and was increased by SO-&kg per min 
increments at 2.min intervals until the development of aide 
effects. Side effects mcluded chest pressure or heaviness, 
dyspnea, tingling or numbness of the arms and legs, nervous. 
ness, headache and nahsea. At this level, the hemodynamic 
prolile was remeasured and drug administration was discon- 
tinued. 
Data review. Patients were classiliad as responders and 
nonresponders on the basis of whether calcium channel 
blocker treatment produced a reduction of ~20% in pulmo- 
nary vascular resistance from baseline values. To evaluate 
patients’ response to the medical interventions, hemody- 
namic measurements at four time pariods were compared: 
1) initial control state (baseline), 2) after the maximally 
tolerated or maximally effective calcium channel blocker 
dose, 3) second control state after ~18 h of maintenance 
calcium channel blocker therapy, and 4) after the maximally 
tolerated dose of adenosine. 
Statiical analyaks. Mean values and standard deviations 
were computed for all variables. Comparisons between the 
initial control state and treatment with a calcium channel 
blocker alone were made with the Student t test for Paired 
data. The effects of the varhms treatment states were com- 
pared by using analysis of variance with confidence intervals 
to test for multiple range. The statistical package used for the 
analysis of variance was Statgraphics 4.0 for personal com- 
puters @TX, Inc.). This method of analysis tests whether 
multiple series are different without caicuiations of p values. 
Comparisons of the effects of drugs between the groups of 
calcium channel blocker responders and nonresponders 
were made with the independent samples I test for p&ad 
variances. Statistical signigcance was L&en at p c 0.05. 
ReStIllS 
The hemodynamic tindings and baseline characteristics of 
the I5 patients studied are presented in Tables I and 2. All 
patients included in the study had pulmonary hypertension 
manifested hv markedly elevated uulmonarv arterv nressure 
(56 * 11 mmHg) and pulmonary &cular r.&.istan~; (I 1.6 + 
5. I U), as well as reduced cardiac index (2.4 5 0.7 liter&tin 
per mr). 
Cakium charmel blr&u eRects. Nifedipine was adminis- 
tered tn I2 patients and titrated to maximal effectiveness 
with doses of 103 L 24 ma lranw 80 to 1tiOk dihiazem was 
utilized in 3 patients, with; mei initial dose’of 360 -+ 49 mg 
(range 300 to 420). The calcium channel b ockers produced a 
12 * 19% reduction i  the mean pulmonary artery pressure 
(p = 0.02) and a 26 * 24% decrease in pulmonary vascular 
resistance (p = 0.01) for the entire group. 
Ten patients were responders, with a mean decnase in 
pulmonary vascular resistance of 39 * 16% (from 8.9 + 4 to 
5.1 f 2 Wood units, p = 0.002) cornwed with no change 
(0 + 12%) in the nonresponders (from 17 f 1.9 to 16.9 f 
2.6 Wood units. P = 1.0) (Fin. 1). Resoonden also had a 
greater reduction-in mean pulmonary a& pressure (from 
53 2 9 IO 44 + I4 mm Hg, 16 ? 22% decrease, P = 0.057) 
than did nonresponders (from 63 + 13 lo 60 f II mm Hg, 
5 + 6% decrease, p = 0.18) (Fig. 2). Cardiac index increased 
significantly (from 2.8 5 0.5 to 3.5 * 0,s litnslmin per m* 
[27 f 1% increase, p = 0.002]) in the responders compared 
with no change ii.8 + 0.3 vs. I.8 t 0.3 literslmin per m* 
[l k 16% decrease, p = LO]) in the nonresponders (Fig. 3). 
Stroke volume increased significantly in the responders 
(from 74 + 19 to 91 + 26 ml [24 ? 23% increase, p = 0.007]) 
but did not change significantly (from 31 f 3 to 31 -c 8 ml 
[2 * 24% increase, p = 0.87)) in the nonresponders (Fig. 4). 
Effaets of eumbining a eaklum chanuel blcnkar and rule- 
mrshte. The maximal dose of adenosine (IBO -c 63 &kg per 
min, range 100 to 300) administered to patients receiving a 
calcium channel blocker was limited by mild side effects. 
Adenosine was well tolerated when given in andition to the 
calcium channel blocker in all patients, and side effects 
appeared to be no worse than those observed with adenosine 
alone in patients with pulmonary hypertension (8). 
In the responders, adenosine further reduced pulmonary 
vascular resistance from the initial control state (baseline) 
value ofS.9 2 4 to 4.6 f 3.2 Wood units (49 f 19% decrease) 
Tabte 1. Hemodvnamic Effects of Calcium Channel Blockers and Adenasine 
2 46 55 55 S6 24 36 3s 3.8 8.6 6.3 bU 6.3 
3 48 19 3.5 JO 3.0 3.6 34 4.0 6.4 2.8 3.8 1.4 
4 48 38 43 27 2.9 3.9 28 3.1 7.2 3.8 6.8 3.0 
s 48 51 49 46 3.6 4.7 3.9 5.5 4.7 3.1 4.6 2.1 
6 49 26 38 33 2.4 3.3 34 6.1 9.8 3.0 4.6 2.2 
7 54 34 38 37 2.7 2.6 3.0 4.4 9.3 5.3 4.9 2.8 
8 56 64 71 70 ?.K 4.3 4.5 5.3 8.1 6.8 6.6 5.7 
9 64 44 47 52 1.6 1.8 1.a ?.6 19.5 9.4 IS.1 12.8 
10 72 69 70 67 2.8 39 PI 46 10.2 7.I 7.0 6.1 
MWI 53 44 49 46 2.8 3.5 ,.4 4.b 8.9 S.I 6.3 4.6 
SD 9 I4 I2 14 0.5 D.8 0.7 I.2 4.0 2.0 2.5 3.2 
NOWXpondc~ 
I 42 42 43 45 I.8 I.5 I.5 0.8 14.1 16.5 IS.4 ?a3 
2 61 60 66 69 l.8 1.6 2.4 I.9 17.1 17.8 17.9 a.0 
3 62 Y S6 63 1.4 I.8 19 2; 16.7 13.6 14.0 Il.1 
4 66 67 64 75 I.7 1.7 1.7 3.0 n.1 21.3 IB.9 12.9 
s 82 73 75 73 2.3 2.4 2.2 2.7 16.7 IS.5 17.3 14.6 
Mean 63 60 65 65 1.8 1.8 1.9 2.1 17.0 16.9 lb.7 17.8 
SD II II IS II 0.1 0.3 0.3 0.8 1.9 2.6 I.8 6.9 
and further reduced mean pulmonary artery pressure from 
53 * 9 to46 * 14 mm Hg (14 e 23% decrease). Cardiac index 
increased from a baseline value of 2.8 f 0.5 to 4.6 -C 
1.2 liters/mitt per m2 (66 +_ 37% increase) and stroke volume 
increased from 74 + 19 to 98 f 28 ml (33 ? 15% incl ease). 
In the responden. stroke volume and mean puhuonary 
artery pressure showed no significant changes induced by 
any drug; however, analysis of cardiac index and pulmonary 
vascular resistance showed adenosine effects to be signifi- 
cantly different tiom baseline. The effect in responders was 
markedly diimnt from that in nonresponders, who had non- 
s@tbicant changes from the baseline value for pulmonary 
vascu!nrresistance (from 17 f 1.9 to 17.8 -c 6.9 Wmd units), 
pulmonary artery pressure (from 63 * I3 to U i I I MI Hg), 
cardiac index(lium 1.8 * 0.3 to2.! 2 0.8 iiterslmittperm2)and 
stroke vobtmo(fmm 31* 3 to 37 + I5 ml). Analysis ofvariance 
for those hemodynamic variables in the nonresponders showed 
that there were no significant changes induced by any drug 
intervention. 
Ctmtpmaiive effects of calcium channel block ibenpy 
and cambhmlion (hcmpy. In the LO patients who responded 
to calcium channel blocker therapy. calcium channel blocker 
maintenance treatment resulted in a 6 ? 19% decrease in 
pulmonary artery pressure (from 53 -C 9 to 49 f 12 mm Hg) 
from the initial control state (baseline) compared with a 14 f 
23% decrease (to 46 f 14 mm Hg) from baseline values in 
combination with adenosine. Maintenance calcium channel 
blockers alone caused a 22 f Zt% increase in cardiac index 
(from 2.8 f 0.5 to 3.4 f 0.7 liters/mitt per mz). whereas 
combination therapy resulted in a 67 ? 37% increase over 
baseline values (increase to 4.6 * 1.2 liter&in per m’). 
Thus, combin4tiot-t therapy resulted in a greater decrease 
(49 + 1%) in pulmonary vascular resistance (from 8.9 -+ 4 to 
4.6 -c 3.2 Wood units) than did calcium channel blocker 
therapy alone (25 ? I%, decrease to 6.3 & 2.5 Wood units). 
Stroke volume also had a signScantly greater (33 + 15% 
increase from baseline vatues) with combination therapy 
(increase from 74 + 19 to !Jg T 28 ml) than with calcium 
channel blocker therapy alone (increase I5 f 13%. to 84 + 
21 ml). For the responders, analysis of the hemodynamtc 
indexes showed only the cardiac index to diier sigui6cantly 
between calcium channel blocker therapy alone and combi- 
nation therapy. In the five patients who did not respond to 
calcium channel blocker therapy, the addition of adenosine 
decreased pulmottary vasculk&istance fmm baseline vtd- 
ues in three patients (by 36%. 13% artd 34%). but increased 
it in two other patients (by 115% and 17%). 
For the entire groun, there was a positive correlation (r = 
0.66. standard error of Y estimate = 30%. p < O.Ot) between 
the reduction in pulmonary vascular resistance from calcium 
channel bloeken at a maximally tolerated dose and the 
reduction achieved with theaddition of adenositte (Fig. 5). In 
general, patients who had the greatest reduction in pulmo- 
narv vascular resistance from calcium channel blocker ther- 
apy ahme had the greatest further reduction by the addition 
of adenosine. Those patients who had the least reduction in 
pulmonary vascularreaistance from caIciutnchanml blocker 
therapy alone had the least benefit from the addition of 
JACC “0,. 21. No. 1 
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Table 2. Hemodynamic Effects of Calcium Channel Blockers and Adenosine 
Right Atrial Presru~ (mm Hg) Pulmonary Capillary Wedge Prerrure (mm Hs) Mm Systemic Arterial Pressure (mm Hgl 
B CO 9, CT B CB B, cr B CB u, CT 
Responders _~ - 
I 9 8 II IO 13 10 I3 12 101 85 97 PI 
2 I 7 5 4 I 5 2 3 87 69 83 79 
3 14 II I? 13 I2 IO 12 14 98 18 a3 78 
4 13 6 6 2 6 7 4 4 92 86 95 92 
5 5 9 6 8 9 12 8 I2 96 73 75 72 
6 5 3 7 5 8 9 II 10 81 76 % 80 
7 5 4 7 5 9 9 II IO 135 88 % 80 
8 14 9 13 12 7 5 II 9 91 79 93 a2 
9 16 22 18 21 9 I5 7 8 92 77 84 81 
IO 7 Ia 8 8 15 I5 13 IO IO3 80 85 76 
Mean 9 9 9 9 9 IO 9 IO 9a 80 88 83 
*SD 5 5 4 5 4 3 4 4 14 6 7 1 
I 8 I3 I2 I2 3 4 8 9 80 72 %I 87 
2 5 8 14 I2 I2 14 I8 9 85 80 a5 78 
3 6 IO 2 8 I9 9 8 I5 89 76 74 87 
4 6 8 9 I2 IO 8 II II 85 73 76 71 
5 IQ II II I5 20 15 IS IO II6 96 87 89 
M&W 7 10 10 I2 13 !O I2 II 83 19 81 82 
SD 2 2 4 2 6 4 4 2 24 9 5 7 
Abbnvialions as in Table I 
adenosine. In one patient, there was a mild (6%) increase in 
pulmonary vascular resistance with the calcium channel 
blocker alone hut a substantial reduction (36%) after the 
addition of adenosine. 
Discussion 
Vasodilators have been shown to produce favorable 
hemodynamic effects in up to 78% of patients with primary 
Figure I. Changes in pulmonary vascular resistance induced by 
calcium channel blockers (CB) and combination therapy (CT) are 
Ftgure 2. Changes in mean pulmonary artery pressure induced by 
shown for patients with primary pulmonary hypertension. Mean 
calcium channel blockers and combination therapy are shown for 
values + SE are diselaved. Patients who remended :suuares) IO 
patierds with primary pulmonary hypensnsion. Mean values + SE 
calcium channel blockers by a decrease in ~ulmona~~vasc&r 
are displayed. Patients who responded @mm) to calcium chanrrcl 
resisianre of 220% arc compared with nonresponders (trirmglas). 
blockers by a decrease in pulmonary vascular resistance of X20% 
The decreases in pulmonary vast&r resistance are significantly 
are eompared with nonresponders (tria+). The decreases in 
grealer in patients who responded to calcium channel blocker 
pulmonary artery pressure arc significantly greaw in patients who 
iherapy. B = baseline; 82 = second control slare. 
responded to calcium channel blocker therapy. Abbreviations as in 
Figure 1. 
pulmonary hypertension (l-3). Whether these effects are 
sustained and improve the prognosis remains unknown. 
Calcium channel blockers at high doses have also been 
shown to cause regression of right ventricular hypertrophy 
(I). The maximal dose of calcium channel blockers may be 
limited, however, by their negative inolropic prop&s or 
untoward effects, thus limiting the maximal potential hemo- 
dynamic improvement from the drugs. 
B CB B2 CT 
lnfervention 
Figure 3. Changes in cardiac index induced by calcium channel 
blockers and combination therapy are shown for patien!s with 
primary pulmonary hypertension. Mean values ? SE are displayed. 
Patients who responded (squarer) lo calcium channel blockers by a 
decrease in pubnoaary vascular resistance of ~20% are compared 
with nonre+xders (lrinagles). Patients who responded to calcium 
channel blocker therapy bad an increase in cardiac index. whereas 
tbe nonxsoonders had minor changes after calcium channel blocker 
therapy and a decrease with the addition of adenosine. Abbrevia- 
tions as in Figure 1. 
Adenosine is an endogenous nucleoside that produces a 
variety of pharmacologic effects, including modulation of 
platelet function and vasodilation (5.6,lW. its vasodilarcr 
etrects have been examined in various vascular beds in 
normal volunteers (S.6.11). Administration of adenosine 
produces a stepwise increase in coronary blood flow with 
increasing doses (5). The mechanism that produces these 
effects is believed to be secondary to stimulation of endo- 
thelial cell and vascular srumth muscle receptors of the Az 
type, which induce vascular smooth muscle relaxation by 
increasing cyclic adenosine monophosphate (AMP) (4). In 
patients with pulmonary hype~tensiott. adenosine was 
shown to decrease systemic vascular resistance and increase 
Figure 4. Changes in stroke voll~me induced by calcium channel 
blwker therapy and combination therapy arc shown for patients 
with primary pulmonary hypertension. Mean values ? SE are 
displajcd. &tients who responded (~uares) IO calcium channel 
blockers by a decrease in pulmonary vascuku reGMance of ZO% 
are compared with nonresponders (triangles). The increases in 
stroke volumeare significanrly greater in patients who responded to 
calcium channel blccker thempy. Abbreviations as in Figure 1. 
20 - 
I 
IO 1 I ! I 
B CB 82 Cl 
Intervention 
Figure 5. Correlation belween percent chan!g? from baseliac in 
pulmonary vascular resistance after combiiation therapy aud with 
calcium channel blocker mcaWhenpy at a maximally tolerated 
dose. Generally, combination therapy caused a greaterreductios io 
oulmonarv vascular resistance rhan did a calcium channel blocker 
ione !n the same patient. 
pulmonary blood Bow without a change in systemic pressure 
(B.IZ). In one sntdy (81, maximally tolerated doses of ade- 
nosine (256 * 46 &g per min) decreased pulmonary 
vascular resistance by 37% and increased cardiac index by 
57%. Adenosine was &so shown to be effective in some 
patients who didnotrespond to nifedipine. As a result ofthai 
study, we questioned whether adenasine could be an alter- 
native agent in patients who had a minimal response to 
calcium channel blockers and whether patients who had a 
marked response to calcium channel blockers could benefit 
further by the addition of adenosine. 
In the present study. adenosioe produced further vasodi- 
Moo primarily in patients who were responders to calcium 
channel blockers. It appears that nonresponders may have 
more advanced disease because they had higher levels of 
pulmonary artery pressure and pulmonary vascular resh- 
lance than did the responders. In the 10 patients who 
responded IO &ium channel blocker therapy, combittaticm 
therapy enhanced the hemodynatnic eifects compared witQ 
monotherapy with a calcium channel blocker. This ohserva- 
tion raises questions regarding our assessment of vasodila- 
tors in primary pulmonary hypertension. Whereas previ- 
ously, we would accept the response to high doses of 
calcium channel blockers as the maximal vasodilation 
achievable, we now must consider those patients who are 
able to respond to calcium channel blockers as candidates 
for additional Lierapy to lower puimonary vascular resis- 
tance to as close to normal as possible. Because calcium 
channel blockers appear to be the most effective current 
therapy, combination therapy needs to be considered, espy- 
cially in patients who benefit from the addition of adenosine. 
Of the five patients who did not respond to a calcium 
channel blocker, two also did not respond to the combina- 
tion therapy with adenosine, but the other three did. These 
findings suggest that adenosine has broader vasodilator 
effects than calcium channel blockers in primary pulmonary 
hypertension. 
We found adeeosine to be a safe drug in patients with 
primary pulmonary hypertension. The systemic hypotensive 
response was mild and nol ofclinical s&-tificance. However, 
in two patients (both nonresponders), the addition of sde- 
nosine to nifedipine caused a substantial decrease in cardiac 
output. Previous studies (4) have indicated that adenosine 
may produce a negative inotropic effect in both atria1 and 
ventricular myocsrdium that is mediated by the extracellular 
A,-receptor. In ventricular myocardial cells., the negmive 
inotropic effect of adenosine is indirect and can be demon- 
strated only when cyclic AMP has been elevated (for exam- 
ple, after catecholamine stimulation) (13). The two patients 
who did not respond to combination therapy also had a 
decrease in cardiac output after nifedipine. This decrease 
was associated with a decrease in stroke volume index (26% 
and 16% in response to the maximal effect of nifedipine and 
47% and 23% in response to the addition of adenosine). We 
found no hemodynamic or clinical characteristics to explain 
why these two patients were more sensitive to the negative 
inotropic effects than were the other nonresponsive patients. 
In four patients (two responders and two nonresponders), 
mean pulmonary artery pressure increased in response to 
one or both drug interventions and was associated with an 
increase in cardiac output. This was always accompanied by 
a decrease in pulmonary vascular resistance. We assume 
that in these patients, the increase in the pulmonary vascular 
flow led to the mcrease in pressure. 
The small number of patients in this study limited its 
statistical power. Although statistical analysis showed that 
treatment wlih combination therapy significantly affected 
only cardiac index, there was a trend ofadded benefit for all 
hemodynamic variables with the addition of adenosine. In 
addition, as a result of the very short half-life and limited 
availability of adenosine, we were unable to assess the 
effects of a long-term adenosine infusion. We also did not 
identify the cellular mechanisms responsible for the herno- 
dynamic effects of adenosine, although they appear to differ 
from those of calcium channel blockers. 
Conclusions. Adenosine is a potent pulmonary artery 
vasodilator and has an ability to further decrease pulmonary 
vascular resistance in patients with primary pulmonary 
hypertension who respond to calcium channel blockers. The 
results of our study provide a basis to pursue further 
research on combination drug therapy in these patients. The 
observation that adenosine further lowered pulmonary vas- 
cular resistance beyond the improvement produced by a 
calcium channel blocker suggests that the pursuit of oral 
aualogues of adenosine as possible therapeutic agents forthe 
treatment of pulmonary hypertension is warranted. The 
mechanism by which pulmouary vasodilation results from 
calcium channel blockers and adenosine also requires fur- 
:hcr investigation. 
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